A Study of GW856553X For the Treatment of Depression
Status:
Terminated
Trial end date:
2008-06-25
Target enrollment:
Participant gender:
Summary
GW856553 is a novel compound, currently in development for the treatment of Major Depressive
Disorder (MDD), and other indications. GW856553 inhibits a protein which is responsible for
the production of some pro-inflammatory molecules, called cytokines. Increased blood levels
of these molecules were seen in populations of MDD patients and this was more apparent in
subjects with severe symptoms, psychomotor retardation and loss of energy. Aim of the present
study is to assess whether GW856553, by inactivating this protein, is able to suppress the
production of the cytokines, and ultimately relieving depression symptoms. In this study
GW856553 or placebo is given to MDD patients 7.5md twice daily for 6 weeks.